Universal reference book for medicines
Product name: CERNILTON ® (CERNILTON)

Active substance: nonappropriate

Type: Phytomedication used for prostate diseases

Manufacturer: Grameenx-Pharma Group of companies (Russia) manufactured by GRAMINEX (USA)
Composition, form of production and packaging
?
Tablets are round, biconvex, from pale yellow to light yellow color, with small impregnations of a darker shade, with engraving of the corporate logo on one side, with a specific smell.
1 tab.

Graminex® G60 (water-soluble fraction of microbiologically fermented extract of plant pollen) 60 mg

Graminex® GFX (fat-soluble fraction of a microbiologically fermented extract of plant pollens) 3 mg

Excipients: microcrystalline cellulose - 237.8 mg, silicon colloidal dioxide - 5.6 mg, magnesium stearate - 3.6 mg.

100 pieces.
- bottles of dark glass (1) - packs of cardboard.
100 pieces.
- bottles of high-density polyethylene (1) - packs of cardboard.
200 pcs.
- bottles of dark glass (1) - packs of cardboard.
200 pcs.
- bottles of high-density polyethylene (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2015.

PHARMACHOLOGIC EFFECT

A medicinal preparation used for diseases of the prostate gland.
Cernilton ® has an anti-inflammatory and anti-edematic effect, promotes the regulation of metabolic processes. One of the pharmacological properties of Cernilton ® is the dose-dependent inhibition of COX and 5-lipoxygenase, which leads to inhibition of the synthesis of mediators of inflammation of the arachidonic acid cycle - prostaglandins and leukotrienes - and, consequently, to a decrease in inflammation and edema of the prostate tissue. The drug helps to eliminate the pain syndrome.
Cernilton ® has a muscle relaxant effect, which leads to a relaxation of the smooth muscle elements of the posterior wall of the urethra and an improvement in urination.

Cernilton ® reduces the volume of the prostate gland due to inhibition of 5? -reductase, selectively blocks?
1- adrenoreceptors of smooth muscle elements of the urethra, has an antiandrogenic effect. Promotes the improvement of erectile function.
INDICATIONS

As part of complex therapy:

- Acute prostatitis;

- chronic prostatitis;

- benign prostatic hyperplasia;

- benign prostatic hyperplasia in combination with prostatitis.

DOSING MODE

The drug is administered orally 30 minutes before meals, with a small amount of water.

With acute prostatitis appoint 4 tab.
3 times / day. Duration of treatment is 3 months.
In chronic prostatitis appoint 1 tab.
3-4 times / day. The duration of the course of treatment is 3-6 months.
With benign prostatic hyperplasia, appoint 2 tab.
3 times / day. The duration of the course of treatment is 12 weeks, but can be increased to 6 months.
SIDE EFFECT

With increased individual sensitivity to the components of the drug , allergic reactions are possible .

Rarely: nausea.

CONTRAINDICATIONS

- Hypersensitivity to the components of the drug.

SPECIAL INSTRUCTIONS

With chronic bacterial prostatitis, the drug can be used only in combination with antibacterial drugs (under the supervision of a doctor).

OVERDOSE

To date, cases of an overdose of Cernilton ® have not been observed.

DRUG INTERACTION

Information on the interaction of the drug Cernilton ® with other drugs is absent.

TERMS OF RELEASE FROM PHARMACY

The drug is approved for use as a means of OTC.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a dry, protected from light, out of reach of children at a temperature of no higher than 25 ° C.
Shelf life - 5 years. Do not use after the expiry date printed on the package.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!